Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBT Margin (2017 - 2025)

Puma Biotechnology's EBT Margin history spans 9 years, with the latest figure at 24.75% for Q4 2025.

  • For Q4 2025, EBT Margin fell 4547.0% year-over-year to 24.75%; the TTM value through Sep 2025 reached 14.58%, up 446.0%, while the annual FY2024 figure was 10.46%, 83.0% up from the prior year.
  • EBT Margin reached 24.75% in Q4 2025 per PBYI's latest filing, down from 16.97% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 25.59% in Q3 2024 to a low of 96.52% in Q3 2021.
  • Average EBT Margin over 5 years is 0.3%, with a median of 5.67% recorded in 2023.
  • Peak YoY movement for EBT Margin: skyrocketed 9601bps in 2022, then tumbled -4547bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 8.01% in 2021, then crashed by -182bps to 6.58% in 2022, then soared by 370bps to 17.74% in 2023, then grew by 17bps to 20.72% in 2024, then tumbled by -219bps to 24.75% in 2025.
  • Per Business Quant, the three most recent readings for PBYI's EBT Margin are 24.75% (Q4 2025), 16.97% (Q3 2025), and 11.76% (Q2 2025).